Finasteride and Hair-Loss Genetics: What Testing Can Tell You

The enzyme 5-alpha-reductase converts testosterone into DHT. Finasteride preferentially inhibits its type 2 form, encoded by SRD5A2. Reducing DHT helps interrupt the androgen signaling involved in follicle miniaturization, the gradual production of thinner hairs in androgenetic alopecia. Mechanism and clinical evidence.

Benefit takes time: the label describes at least three months of use before improvement is generally observed, with continued treatment needed to maintain benefit. Preserving hair as well as increasing growth can matter when assessing results.

This mechanism helps explain why researchers investigate both the enzyme that finasteride inhibits and the androgen receptor through which hormones signal. A gene can be biologically relevant even when its variants are not yet useful for predicting an individual treatment outcome.

Two parts of the androgen pathway studied in finasteride response

Gene	Why researchers study it
SRD5A2	Encodes type 2 5-alpha-reductase, the main enzyme target of finasteride. Changes in the protein can alter its behavior in laboratory experiments.
AR	Encodes the androgen receptor. Researchers have investigated whether the lengths of repeated DNA sequences in this gene relate to treatment response.

Functional variation in the drug's target

There is experimental evidence that genetic differences can affect finasteride's target. A biochemical study found that SRD5A2 variants altered how the enzyme was inhibited by finasteride and dutasteride. This establishes biological plausibility, but an enzyme-inhibition experiment does not directly measure hair regrowth or side effects in patients. Makridakis and Reichardt, 2005.

Androgen receptor repeat lengths

AR contains DNA sequences called CAG and GGC repeats. In a study of 488 men, shorter combined repeat lengths were broadly associated with greater improvement during finasteride treatment. However, initial hair-loss severity also differed between groups, which complicates interpretation. Wakisaka et al., 2005.

A later, much smaller study involving 25 men with androgenetic alopecia found an association with GGC repeat length, but not CAG repeat length. These results illustrate why a promising association needs replication and a clear, consistent definition before it can support a personal report. Neither study establishes a generally applicable cutoff for choosing finasteride or its dose. Ghassemi et al., 2019.

Panels combining several genetic markers

A 2025 study of a 26-SNP panel reported associations with response to several hair-loss treatments, including finasteride. It used retrospective data and included small treatment subgroups. Adherence, dose, and formulation could not be fully controlled; the authors acknowledged the need for prospective, controlled validation. Gaboardi et al., 2025; study limitations and author responses.

The missing step is a sufficiently supported interpretation of a specific genetic result. Finasteride has an established treatment role and relevant genetic research. Gene2Rx has not adopted a variant-specific guideline that translates that research into an individual response, dose, or side-effect assessment.

The studies above address different questions: how an enzyme behaves, whether repeat length correlates with improvement, or whether a multi-marker panel is associated with treatment outcomes. Their findings do not combine automatically into a reliable prediction for a new patient. Results also need to be understood in the context of the population, formulation, treatment duration, and other medicines used.

To support a future interpretation, useful evidence would include independent replication of a defined variant or marker, consistent response measurements, and a clear explanation of what the result means for the person receiving it. A finding about hair-loss susceptibility alone would not answer whether finasteride will work or whether side effects will occur.

For now, Gene2Rx provides no finasteride responder category, genotype-based dose, or genetic reassurance about side effects. Finasteride is excluded from report medication totals. Its presence in the drug library is educational and does not indicate report coverage.

The Gene2Rx topical minoxidil guideline describes a specific functional variant, SULT1A1 rs1042028, in an enzyme involved in activating minoxidil. Its scope is information about that inherited finding and topical minoxidil response.

Finasteride acts on DHT production through a different target. A SULT1A1 result does not determine how strongly finasteride will inhibit 5-alpha-reductase or whether your hair will respond. Even where a research panel reports associations across several medicines, each proposed interpretation needs its own supporting evidence. Gene2Rx does not use a minoxidil result to recommend switching to finasteride.

Treatment decisions can draw on your diagnosis, pattern and duration of hair loss, previous treatment, priorities, and medical history. Photographs taken under consistent conditions can help make a discussion about change over time more concrete.

Discuss possible sexual side effects and mood symptoms. The label includes postmarketing reports of sexual dysfunction continuing after discontinuation and depression or suicidal thoughts. Finasteride also lowers PSA, which matters when interpreting prostate blood tests. People who are pregnant or may become pregnant should not handle crushed or broken tablets because of potential harm to a male fetus. Read the full safety information.

The evidence and labeling discussed here primarily concern oral finasteride. A different formulation requires its own review of benefits and risks. Gene2Rx currently provides no personalized genetic assessment for either oral or topical finasteride.

For related information, explore dutasteride, topical minoxidil, and the hair-loss medication overview.

• DailyMed: finasteride 1 mg prescribing information. Approved use, mechanism, clinical studies, and precautions.
• Makridakis and Reichardt (2005): pharmacogenetic analysis of human steroid 5-alpha-reductase type II. Laboratory evidence on variation in enzyme inhibition.
• Wakisaka et al. (2005): finasteride response and androgen receptor repeat lengths. A study in 488 men.
• Ghassemi et al. (2019): androgen receptor repeat polymorphisms and finasteride response. A smaller study with differing CAG and GGC findings.
• Gaboardi et al. (2025): 26-SNP panel study of androgenetic alopecia therapy. Retrospective treatment-response research; see also the authors' discussion of its limitations.